Bajgliptin Duo Tablet 50/500 mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Bainex Co., Ltd.
MFDS item code 201507540 · Approved 2015.11.03
This product's status changed to Approval withdrawn on 2024.10.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used along with diet and exercise to help control blood sugar in patients with type 2 diabetes. Initially, it is used when blood sugar control is difficult with monotherapy, and the patient has no prior experience with diabetes medication. It can also replace the use of metformin or sitagliptin when blood sugar control is insufficient with these drugs alone or in combination. If blood sugar control is still inadequate with metformin in conjunction with sulfonylurea or in conjunction with thiazolidinedione, this medication can be added. Lastly, it may also be used when there is inadequate effect with insulin and metformin therapy. In other words, this medication is used to improve blood sugar control in conjunction with various existing treatments.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose of this medicine is 1 tablet of 50/500 mg twice daily. The dose may be increased to 1 tablet of 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin must not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medicine for patients who do not achieve adequate glycemic control with metformin monotherapy is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their existing doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined taking the patient's blood glucose level and existing dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administering this medicine with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in treatment for type 2 diabetes may cause changes in glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment must not be initiated with this medicine, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function decreases to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication is used for the treatment of diabetes and contains sitagliptin and metformin. Before taking this medication, check for any history of allergic reactions, and if serious allergic symptoms or skin conditions occur, stop taking the medication immediately and consult a doctor. Acute pancreatitis, a serious pancreatic disorder, may occur infrequently; therefore, if symptoms such as abdominal pain, nausea, or vomiting develop, inform medical staff immediately. It should not be administered to patients with moderate to severe renal impairment, severe infections, or dehydration, or patients with acute cardiac disease. It is safer for pregnant women or women who may become pregnant, as well as nursing women, to avoid taking this medication. This medication may cause hypoglycemic symptoms; therefore, it is important to maintain regular meal times, avoid excessive exercise or alcohol intake, and be aware that the risk of hypoglycemia may increase when combined with other hypoglycemic agents. Regular monitoring of renal function and blood tests to check for adverse effects of this medication is important, and vitamin B12 levels should also be checked periodically. Patients with upcoming surgeries should discontinue use of this medication 48 hours before surgery and resume treatment only after renal function is confirmed to be normal post-surgery. Adverse effects such as diarrhea, nausea, headache, upper respiratory infections have been reported with this medication; if severe joint pain or skin rashes develop, a doctor should be consulted immediately. Alcohol consumption may increase the risk of adverse effects; thus, excessive drinking should be avoided while taking this medication. During the use of this medication, it is necessary to consistently maintain diet, exercise, regular blood sugar monitoring, and consultations with healthcare professionals to ensure blood sugar control.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air from entering, at room temperature between 1 to 30 degrees Celsius. This will help maintain the effectiveness of the medication for an extended period.
Pink oval film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Bainex Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.